Alkermes Inc: Premium Company Profile
Scope
Report Highlights
Reasons to Purchase
Table of Contents
- Overview - page 1
- Catalyst - page 1
- Summary - page 1
- Table of Contents - page 2
- Table of figures - page 3
- Table of tables - page 4
- Company Structure - page 5
- Company Overview and Key Facts - page 5
- Business Description - page 6
- Landmark Products and Services - page 6
- Medisorb (Injectable Extended-Release Technology) - page 6
- Landmark Products and Services - page 6
- History - page 7
- M&A History - page 8
- Enzytech - page 8
- Medisorb Technologies - page 8
- Advanced Inhalation Research (AIR) - page 8
- M&A History - page 8
- Locations and Subsidiaries - page 10
- Company Financials - page 11
- Stock Market Performance - page 11
- P&L - page 14
- Balance Sheet - page 17
- Cash Flow - page 17
- Business Segment Performance - page 18
- Products & Services - page 21
- Marketed Products - page 21
- Risperdal Consta - page 21
- Vivitrol - page 21
- Pipeline Products - page 22
- In-house Pipeline - page 22
- ALKS 29 - page 22
- Collaboration Pipeline - page 22
- Air Insulin - page 22
- Exenatide LAR - page 23
- Air PTH - page 23
- ALKS 27 - page 24
- In-house Pipeline - page 22
- Technologies - page 24
- Medisorb (Injectable Extended-Release Technology) - page 24
- AIR (Pulmonary technology) - page 24
- AC Forecast Product Sales - page 25
- Marketed Products - page 21
- Competitors and Strategic Business Relationships - page 26
- Key Competitors - page 26
- Key Suppliers - page 26
- Key Clients - page 27
- Shareholding Structure - page 28
- Strategy - page 29
- Company View - page 29
- Corporate Strategy - page 30
- SWOT Analysis - page 31
- Overview - page 31
- Strengths - page 32
- Drug Delivery Technologies - page 32
- Manufacturing capabilities - page 32
- Weaknesses - page 33
- No product sales - page 33
- Weak in-house pipeline - page 33
- Opportunities - page 34
- AIR Insulin - page 34
- Opportunity in Japan - page 34
- Threats - page 35
- Competition - page 35
- Absence of sales and marketing infrastructure and capabilities - page 35
- Value Chain Analysis - page 36
- Overview - page 36
- Product Development - page 37
- Manufacturing - page 38
- Scorecard - page 39
- Overview - page 39
- Scorecard Analysis - page 40
- Key Employees - page 41
- List of Key Employees - page 41
- Key Employee Biographies - page 42
- David A Broecker - page 42
- Richard F.Pops - page 42
- Michael A.Wall - page 42
- Floyd E.Bloom - page 43
- Robert A.Breyer - page 43
- Gerri Henwood - page 43
- Paul J.Mitchell - page 44
- Alexander Rich - page 44
- Paul Schimmel - page 44
- Mark Skaletsky - page 45
- Kathryn L.Biberstein - page 45
- Elliot W.Ehrich - page 45
- James M.Frates - page 46
- Michael J.Landline - page 46
- Gordon G.Pugh - page 46
- F.Ken Andrews - page 47
- Madeline D.Coffin - page 47
- Financial and Operational Overview - page 48
- Financial and Operational Overview - page 48
- APPENDIX - page 51
- Ask the analyst - page 51
- Datamonitor consulting - page 51
- Disclaimer - page 51
- List of Tables
- Table 1: Alkermes - Key Facts - page 5
- Table 2: Alkermes - Locations and Subsidiaries - page 10
- Table 3: Alkermes - Year-End Share Price and Market Capitalization, 2002-2006 ($) - page 11
- Table 4: Alkermes - Key Events Impacting Share Price Performance - page 12
- Table 5: Alkermes - Operating Revenue/Cost Analysis, 2002-2007 ($ Mn) - page 14
- Table 6: Alkermes - Operating Cost Ratio Analysis, 2002-2007 (% of total revenues) - page 16
- Table 7: Alkermes - Balance Sheet, 2002-2006 ($ Mn) - page 17
- Table 8: Alkermes - Cash Flow, 2002-2006 ($ Mn) - page 17
- Table 9: Alkermes - Revenue Breakdown by Division, 2002-2007 ($ Mn) - page 18
- Table 10: Alkermes - Marketed Products - page 21
- Table 11: Alkermes - In-house Pipeline Products - page 22
- Table 12: Alkermes - Collaboration Products - page 22
- Table 13: Alkermes - Forecast Sales, 2006-2011 ($ Mn) - page 25
- Table 14: Alkermes - Key Competitors - page 26
- Table 15: Alkermes - Key Suppliers - page 27
- Table 16: Alkermes - Key Clients - page 27
- Table 17: Alkermes - Key Shareholders - page 28
- Table 18: Alkermes - SWOT Analysis Summary - page 31
- Table 19: Alkermes - Value Chain Analysis - page 37
- Table 20: Alkermes - Scorecard - page 39
- Table 21: Alkermes - Key Employees - page 41
- Table 22: Alkermes - Financial and Operational Overview - page 49
- List of Figures
- Figure 1: Alkermes - Operating Revenue/Cost Analysis, 2002-2007 ($ Mn) - page 15
- Figure 2: Alkermes - Key Strategic Revenues, 2003-2007 ($ Mn) - page 20
Other users found this report page using the following search terms: alkermes medisorb air history madeline revenue d alkermesincshareholdingstructure biberstein l
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.